2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
March 31, 2023
Article
As the first clinical trial of the drug novobiocin is about to open for patients with cancers carrying BRCA gene mutations, new research at Dana-Farber Cancer Institute shows the drug poses a double threat to tumor cells.
March 30, 2023
Video
Ursula A. Matulonis, MD, discusses common toxicities associated with mirvetuximab soravtansine-gynx, and how to properly manage these treatment-related adverse effects for patients with folate receptor alpha-high ovarian cancer.
March 29, 2023
Article
Dana-Farber Cancer Institute researchers outline the complexities of colorectal cancer and the research needed to map out a path toward understanding it.
March 27, 2023
Video
Ursula A. Matulonis, MD, discusses final overall survival results from the phase 3 NOVA trial in patients with ovarian cancer.
March 20, 2023
Podcast
Dr Tolaney discusses the FDA approval of sacituzumab govitecan in patients with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer; key data from the TROPiCS-02 trial; and how this agent can fulfill unmet needs for this patient population.
March 17, 2023
Article
Investigators are assessing the combination of avelumab and lurbinectedin as maintenance therapy for patients with metastatic urothelial carcinoma who achieve a response or stable disease following first-line, platinum-based chemotherapy in a single-arm phase 2 trial.
March 14, 2023
Video
Paul G. Richardson, MD, discusses the impact of combining proteasome inhibitors and monoclonal antibodies in multiple myeloma.
March 13, 2023
Article
Despite a perhaps overwhelming number of combination regimens available for use in the frontline setting for patients with renal cell carcinoma, treatment decisions can still largely boil down to a patient’s risk status. For second-line therapy, investigators are looking to contemporary trials for guidance.
March 10, 2023
Article
Given the current lack of positive phase 3 immunotherapy trials for glioblastoma, a misconception held by oncologists and neuro-oncologists is that immunotherapy has no place in this malignancy.
March 09, 2023
Article
The progression-free survival benefit associated with the combination of nivolumab plus cabozantinib compared with sunitinib was largely independent of PD-L1 and c-MET status in previously untreated patients with advanced or metastatic renal cell carcinoma.
March 07, 2023
Article
The advent of effective first-generation TKIs has allowed for improvements among patients with Philadelphia chromosome–positive disease, which is traditionally associated with a poor prognosis, as it generally does not respond to conventional chemotherapy options.
February 28, 2023
Video
Paul L. Nguyen, MD, discusses primary findings from the phase 2 FORMULA-509 trial in prostate cancer.
February 25, 2023
Article
Patients with chronic lymphocytic leukemia, including those with difficult-to-treat disease classes such as double refractory, are quickly gaining more effective treatment options.
February 20, 2023
Video
Bradley McGregor, MD, discusses the investigation of cabozantinib plus atezolizumab in patients with non–clear cell renal cell carcinoma.
February 20, 2023
Article
Trauma and stress related to the COVID-19 pandemic, coupled with subsequent widespread labor shortages, have turned burnout, which was an endemic issue in medicine, to a pandemic in health care.
February 16, 2023
Podcast
Drs Flinn, Lamanna, Brown, and Tam discuss the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.
February 16, 2023
Article
ADI-001, a first-in-class, allogeneic gamma delta1 CAR T-cell therapy, elicited responses and demonstrated a favorable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
February 16, 2023
Article
Sacituzumab govitecan, a novel antibody drug-conjugate therapy has been granted accelerated approved by the U.S. Food and Drug Administration for the treatment of metastatic HR+, HER2- breast cancer.
February 14, 2023
Video
Atish D. Choudhury, MD, PhD, discusses the need for expanded genomic profiling and additional biomarkers to better predict which patients with metastatic castration-resistant prostate cancer could benefit from treatment with PARP inhibitor–based combinations.
February 14, 2023
Video
Stephanie A. Berg, DO, discusses key ongoing trials in metastatic urothelial carcinoma.